Literature DB >> 16170606

Cutaneous phaeohyphomycosis due to Alternaria infectoria.

Damien Dubois1, Marc Pihet, Christian Le Clec'h, Anne Croué, Hugues Beguin, Jean-Philippe Bouchara, Dominique Chabasse.   

Abstract

Here we report a case of cutaneous alternariosis in a 74-year-old man treated by corticotherapy for myasthenia, and presenting with papular, crusted lesions on the left elbow and the right knee. Histological examination of the biopsy specimens showed fungal hyphae associated with round-shaped cells which were highly suggestive of alternariosis. Mycological culture allowed the isolation of a dematiaceous fungus which was identified as a member of the Alternaria infectoria species-group. This was confirmed by PCR amplification and sequencing of the internal transcribed spacer domain of the gene encoding nuclear ribosomal DNA and of the mitochondrial small subunit ribosomal DNA domain. The fungus was therefore referred to the Scientific Institute of Public Health where it was identified as Alternaria infectoria, on the basis of its very small 1 or 2-celled conidia often arranged in long chains and presenting with very long secondary conidiophores. Corticotherapy was stopped and a local antifungal treatment with ketoconazole was initiated, allowing the stabilisation of the cutaneous lesions within 2 months.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16170606     DOI: 10.1007/s11046-005-5259-5

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  11 in total

1.  Case report. Cutaneous phaeohyphomycosis due to Alternaria alternata.

Authors:  P Mayser; M Nilles; G S de Hoog
Journal:  Mycoses       Date:  2002-10       Impact factor: 4.377

2.  Phaeohyphomycosis caused by Alternaria infectoria in a renal transplant recipient.

Authors:  T Halaby; H Boots; A Vermeulen; A van der Ven; H Beguin; H van Hooff; J Jacobs
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

3.  [Cutaneous Alternaria infectoria infection after liver transplantation].

Authors:  C Laumaillé; F Le Gall; B Degeilh; E Guého; M Huerre
Journal:  Ann Pathol       Date:  1998-07       Impact factor: 0.407

4.  Alternaria osteomyelitis.

Authors:  J Garau; R D Diamond; L B Lagrotteria; S A Kabins
Journal:  Ann Intern Med       Date:  1977-06       Impact factor: 25.391

5.  Itraconazole treatment of phaeohyphomycosis.

Authors:  P K Sharkey; J R Graybill; M G Rinaldi; D A Stevens; R M Tucker; J D Peterie; P D Hoeprich; D L Greer; L Frenkel; G W Counts
Journal:  J Am Acad Dermatol       Date:  1990-09       Impact factor: 11.527

Review 6.  Utilization of the internal transcribed spacer regions as molecular targets to detect and identify human fungal pathogens.

Authors:  P C Iwen; S H Hinrichs; M E Rupp
Journal:  Med Mycol       Date:  2002-02       Impact factor: 4.076

7.  Sporotrichoid phaeohyphomycosis due to Alternaria infectoria.

Authors:  R Gerdsen; M Uerlich; G S De Hoog; T Bieber; R Horré
Journal:  Br J Dermatol       Date:  2001-09       Impact factor: 9.302

8.  Rapid molecular diagnosis of posttraumatic keratitis and endophthalmitis caused by Alternaria infectoria.

Authors:  Consuelo Ferrer; Javier Montero; Jorge L Alió; José L Abad; José M Ruiz-Moreno; Francisca Colom
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

9.  Molecular taxonomy of the alternaria and Ulocladium species from humans and their identification in the routine laboratory.

Authors:  G S de Hoog; R Horré
Journal:  Mycoses       Date:  2002-10       Impact factor: 4.377

10.  PCR primers that allow intergeneric differentiation of ascomycetes and their application to Verticillium spp.

Authors:  K N Li; D I Rouse; T L German
Journal:  Appl Environ Microbiol       Date:  1994-12       Impact factor: 4.792

View more
  1 in total

1.  Alternaria infectoria brain abscess in a child with chronic granulomatous disease.

Authors:  E Hipolito; E Faria; A F Alves; G S de Hoog; J Anjos; T Gonçalves; P V Morais; H Estevão
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-09-25       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.